###begin article-title 0
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway
###end article-title 0
###begin p 1
L. Wang and T. Yi contributed equally to this paper.
###end p 1
###begin p 2
###xml 391 394 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 440 443 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 431 443 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 636 637 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
Although the Th17 subset and its signature cytokine, interleukin (IL)-17A (IL-17), are implicated in certain autoimmune diseases, their role in cancer remains to be further explored. IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear. We show that growth of B16 melanoma and MB49 bladder carcinoma is reduced in IL-17-/- mice but drastically accelerated in IFN-gamma-/- mice, contributed to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor growth. Adoptive transfer studies and analysis of the tumor microenvironment suggest that CD4+ T cells are the predominant source of IL-17. Enhancement of tumor growth by IL-17 involves direct effects on tumor cells and tumor-associated stromal cells, which bear IL-17 receptors. IL-17 induces IL-6 production, which in turn activates oncogenic signal transducer and activator of transcription (Stat) 3, up-regulating prosurvival and proangiogenic genes. The Th17 response can thus promote tumor growth, in part via an IL-6-Stat3 pathway.
###end p 2
###begin p 3
###xml 225 244 225 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Weaver et al., 2006</xref>
###xml 499 520 496 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Chen and O&#8217;Shea, 2008</xref>
A major advance in understanding the role of various T cell subsets in disease has been the recent identification of the Th17 subset, characterized by the production of IL-17A (IL-17), as well as the related IL-17F cytokine (Weaver et al., 2006). Just as with the Th1 and Th2 subsets, whose development and propagation are mediated by specific cytokines, Th17 development is selectively induced by a combination of IL-6 and TGF-beta, whereas the IL-12 family member IL-23 supports Th17 propagation (Chen and O'Shea, 2008). The ability of IL-6 to divert TGF-beta-stimulated T cells away from regulatory T cell differentiation and toward Th17 cell differentiation, as well as the distinct roles of IL-12 and IL-23 in supporting Th1 and Th17 propagation, respectively, emphasizes the high degree of regulation involved in T cell development and function under various physiological states.
###end p 3
###begin p 4
###xml 139 158 139 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Khader et al., 2007</xref>
###xml 448 467 448 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Khader et al., 2007</xref>
###xml 691 712 691 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Bettelli et al., 2007</xref>
###xml 789 808 789 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Weaver et al., 2007</xref>
Th17 responses appear to be physiologically important in pulmonary bacterial immunity as well as immunity to certain intestinal pathogens (Khader et al., 2007). The specific role of IL-17 and other cytokines produced by Th17 cells in these responses remains to be completely elucidated, though direct effects on epithelial cells as well as recruitment of neutrophils seem to be important factors, depending on the site and nature of the infection (Khader et al., 2007). Pathologically, Th17 responses are involved in certain inflammatory and autoimmune diseases, including inflammatory bowel disease, rheumatoid arthritis, autoimmune iritis, and central nervous system autoimmune syndromes (Bettelli et al., 2007). CD8 T cells and non-T cells have been reported to produce Th17 cytokines (Weaver et al., 2007), including IL-17, but the role of non-T cell-derived IL-17 remains to be further defined.
###end p 4
###begin p 5
###xml 198 217 194 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Kaplan et al., 1998</xref>
###xml 219 236 215 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Dunn et al., 2006</xref>
###xml 430 457 426 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Colombo and Mantovani, 2005</xref>
###xml 749 771 741 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Langowski et al., 2006</xref>
###xml 866 871 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-23</italic>
###xml 872 875 864 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p19</italic>
###xml 930 935 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-12</italic>
###xml 936 939 928 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p35</italic>
###xml 946 970 938 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kortylewski et al., 2009</xref>
###xml 1036 1053 1028 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Chen et al., 2006</xref>
###xml 1210 1231 1202 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bromberg et al., 1999</xref>
###xml 1233 1248 1225 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Yu et al., 2007</xref>
###xml 1470 1494 1462 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Kortylewski et al., 2005</xref>
###xml 1590 1611 1582 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Miyahara et al., 2008</xref>
###xml 1613 1632 1605 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Sfanos et al., 2008</xref>
###xml 1634 1652 1626 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Zhang et al., 2008</xref>
###xml 1735 1756 1727 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Numasaki et al., 2003</xref>
###xml 1758 1779 1750 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Numasaki et al., 2005</xref>
###xml 1781 1802 1773 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Muranski et al., 2008</xref>
###xml 1804 1820 1796 1812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Nam et al., 2008</xref>
###xml 1822 1842 1814 1834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kryczek et al., 2009</xref>
###xml 1844 1861 1836 1853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Xiao et al., 2009</xref>
###xml 1863 1881 1855 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Zhang et al., 2009</xref>
The immune system can act as an extrinsic suppressor of tumors, and the importance of Th1, characterized by IFN-gamma and type 1 IFNs, in inhibiting tumor incidence and growth has been established (Kaplan et al., 1998; Dunn et al., 2006). Recent studies, however, have also demonstrated a critical role of certain immune cells, via production of specific cytokines or growth factors, in promoting carcinogenesis and tumor growth (Colombo and Mantovani, 2005). This opposing role of the immune system in tumor immune surveillance and cancer promotion is exemplified by a pair of related cytokines: although IL-12 clearly possesses antitumor activity via both NK activation and Th1/IFN-gamma induction, IL-23 has been found to promote carcinogenesis (Langowski et al., 2006). Specific STAT pathways regulate the IL-12/IL-23 balance, with Stat3 coordinately activating IL-23/p19 gene transcription while inhibiting expression of the IL-12/p35 gene (Kortylewski et al., 2009). Similar to IL-23, IL-17 expression is also regulated by Stat3 (Chen et al., 2006), which is an oncogene persistently activated in tumor cells and tumor stromal cells, promoting tumor cell survival, proliferation, and tumor angiogenesis (Bromberg et al., 1999; Yu et al., 2007). Persistent activation of Stat3 in tumor cells and in tumor-associated immune cells also promotes accumulation of tumor myeloid-derived suppressor cells and tumor regulatory T cells, leading to tumor immune suppression (Kortylewski et al., 2005). Although IL-17-producing T cells have been found in increased numbers within certain tumors (Miyahara et al., 2008; Sfanos et al., 2008; Zhang et al., 2008), it remains controversial whether IL-17 promotes or inhibits cancer progression (Numasaki et al., 2003; Numasaki et al., 2005; Muranski et al., 2008; Nam et al., 2008; Kryczek et al., 2009; Xiao et al., 2009; Zhang et al., 2009). Importantly, the underlying mechanisms of IL-17 in modulating tumor growth is still poorly understood.
###end p 5
###begin title 6
RESULTS AND DISCUSSION
###end title 6
###begin title 7
Th17 cells can promote tumor growth
###end title 7
###begin p 8
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 194 213 190 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Kaplan et al., 1998</xref>
###xml 215 232 211 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Dunn et al., 2006</xref>
###xml 283 306 279 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Harrington et al., 2005</xref>
###xml 343 352 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;</italic>
###xml 368 382 360 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17IFN-&#947;</italic>
###xml 429 432 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 424 432 412 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 443 446 427 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 434 446 422 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 461 464 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 469 472 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 452 472 436 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 604 607 584 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 599 607 579 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 648 656 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 709 728 685 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Kaplan et al., 1998</xref>
###xml 730 747 706 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Dunn et al., 2006</xref>
###xml 769 778 745 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;</italic>
###xml 888 896 860 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 924 927 892 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 932 935 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 915 935 887 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 1004 1007 968 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 995 1007 963 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 1014 1022 978 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
We assessed the role of IL-17 in modulating tumor growth in mice with genetically ablated IL-17 alleles (IL-17 KO). Because IFN-gamma-producing Th1 T cells generally provide antitumor immunity (Kaplan et al., 1998; Dunn et al., 2006) and are known to restrain Th17 cell development (Harrington et al., 2005), we also evaluated tumor growth in IFN-gamma KO mice and in IL-17IFN-gamma double KO mice. Sex- and age-matched WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- B6 mice were challenged with B16 melanoma. Results from these experiments showed that tumor growth rate was reduced in the B6 IL-17-/- mice when compared with WT B6 controls (Fig. 1 A). As expected from the antitumor role of IFN-gamma (Kaplan et al., 1998; Dunn et al., 2006), in B6 mice lacking IFN-gamma alleles, B16 tumors appeared earlier and the tumor growth rate was drastically increased relative to the WT (Fig. 1 A). Importantly, in IFN-gamma-/-IL-17-/- mice, tumor growth was significantly reduced compared with IFN-gamma-/- mice (Fig. 1 A), supporting a tumor-promoting role of Th17 cells in the B16 subcutaneous tumor model.
###end p 8
###begin p 9
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17 promotes tumor growth, which is mainly mediated by T cells.</bold>
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 128 136 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 147 150 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 138 150 138 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 165 168 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 173 176 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 156 176 152 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 216 217 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 309 312 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 304 312 294 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 323 326 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 314 326 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 341 344 323 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 349 352 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 332 352 318 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 362 363 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 592 593 574 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 875 878 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 870 878 844 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag-2<sup>&#8722;/&#8722;</sup></italic>
###xml 924 927 894 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 915 927 889 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 1046 1049 1012 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1054 1057 1020 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1037 1057 1007 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 1097 1098 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 879 883 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
IL-17 promotes tumor growth, which is mainly mediated by T cells. (A) 105 B16 tumor cells were injected subcutaneously into WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- B6 mice. Data represent means +/- SEM (n = 12 mice per group from three independent experiments). (B) MB49 tumor growth in WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- B6 mice (n = 8 mice from two experiments). (C and D) Intratumoral IL-17 promotes cancer metastasis. (C) MB49 tumor cells were injected subcutaneously into the four groups of mice as indicated, and lung colonies were enumerated 3 wk later (n = 4; P = 0.01). (D) Representative photos of the lung tissues from each group with arrows indicating lung metastasis are shown. Bars: (top) 1,000 microm; (bottom) 500 microm. (E) IL-17-mediated tumor-promoting effects are mainly mediated by T cells. Rapid B16 tumor growth in Rag-2-/- mice receiving adoptive transfer of IFN-gamma-/- T cells was observed compared with significantly reduced growth rates in mice receiving adoptive-transferred IFN-gamma-/-IL-17-/- T cells. Data represent means +/- SEM (n = 11 mice from two experiments).
###end p 9
###begin p 10
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 62 70 62 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 81 84 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 72 84 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 99 102 91 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 107 110 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 90 110 86 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 186 189 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 181 189 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 220 228 212 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 304 307 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 295 307 287 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 338 343 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 411 419 395 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 469 472 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 477 480 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 460 480 444 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 513 516 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 508 516 488 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 573 576 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 568 576 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 587 590 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 578 590 558 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 605 608 577 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 613 616 585 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 616 572 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 909 912 877 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 900 912 872 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 977 992 945 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, C and D</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
We also evaluated growth of the MB49 bladder carcinoma in WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- mice. Similar to B16, we observed growth inhibition of MB49 tumors in IL-17-/- mice relative to WT controls (Fig. 1 B). Furthermore, MB49 tumor growth was significantly accelerated in IFN-gamma-/- relative to WT mice. Ablating IL-17 diminished accelerated tumor growth caused by a lack of IFN-gamma (Fig. 1 B). However, the tumor growth rate in the IFN-gamma-/-IL-17-/- B6 mice was higher than in IL-17-/- mice. Thus, the general pattern of tumor growth in IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- mice was similar for B16 and MB49 tumors despite their different tissue origins. Subcutaneous MB49 tumors also naturally metastasize to lungs; we therefore assessed whether levels of lung metastasis correlate with tumor size in the four groups of mice. Ablating IL-17 in both WT and IFN-gamma-/- mice was associated with a decreased number of lung metastases (Fig. 1, C and D).
###end p 10
###begin p 11
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2<sup>&#8722;/&#8722;</sup></italic>
###xml 179 182 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 170 182 170 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 234 240 230 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 260 263 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 268 271 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 251 271 247 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 318 321 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 326 329 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 309 329 301 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 398 401 382 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 389 401 377 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 411 419 395 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
To assess whether T cells were a primary source of IL-17 for promoting tumor growth, we reconstituted Rag2-/- mice by adoptive T cell transfer with purified T cells from IFN-gamma-/- mice that display high levels of IL-17 production (Fig. 2), or from IFN-gamma-/-IL-17-/- mice. Tumor growth in mice receiving IFN-gamma-/-IL-17-/- T cells was significantly reduced compared with mice given IFN-gamma-/- T cells (Fig. 1 E), suggesting that the increased tumor growth, caused by elevated IL-17 production, was mainly contributed by T cells.
###end p 11
###begin p 12
###xml 0 99 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Reciprocal relationship between IFN-&#947; and IL-17 production by tumor-infiltrating T lymphocytes.</bold>
###xml 230 231 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 448 449 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 499 502 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 494 502 490 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 513 516 505 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 504 516 500 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 530 533 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 538 541 526 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 521 541 513 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 747 748 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 756 757 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 930 931 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 974 977 956 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 969 977 951 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 1043 1044 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1196 1197 1170 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1211 1212 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
Reciprocal relationship between IFN-gamma and IL-17 production by tumor-infiltrating T lymphocytes. Single-cell suspensions were prepared from B16 or MB49 tumors harvested 20 d after tumor implantation. (A) IL-17 expression in CD4+ T cells from B16 (top) or MB49 (bottom) tumors; flow cytometric patterns shown (one tumor per group) are representative of three independent experiments. Percentages are shown. (B) IL-17 secretion by intratumoral CD4+ T cells sorted from B16 tumors grown in WT, IL-17-/-, IFN-gamma-/-, or IFN-gamma-/-IL-17-/- mice was assessed by ELISA after a 24-h culture, combining results from three independent experiments of three to four pooled tumor samples (P = 0.001). Data represent means +/- SEM. (C) Percentages of CD4+ and CD8+ T cells within the total intratumoral leukocyte population harvested on days 20 (top row) and 14 (second from top row). (second from bottom row) IFN-gamma expression in CD8+ T cells derived from tumors of WT or IL-17-/- mice. (bottom row) IFN-gamma expression by tumor-infiltrating CD4+ T cells (representative of three independent experiments). Percentages are shown. (D) Increased secretion of IFN-gamma by sorted tumor-infiltrating CD8+ (top) and CD4+ (bottom) T cells, combining results from three independent experiments of pooled tumor samples (P = 0.002). Data represent means +/- SEM. TIL, tumor-infiltrating T lymphocytes.
###end p 12
###begin title 13
Reciprocal relationship between IL-17 and IFN-gamma production in tumors
###end title 13
###begin p 14
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 190 193 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 181 193 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 208 211 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 216 219 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 199 219 195 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 374 382 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 458 461 442 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 449 461 437 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 468 476 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 588 589 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 610 613 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 601 613 585 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 658 661 634 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 666 669 642 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 649 669 629 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 686 694 662 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 764 765 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
We performed intracellular cytokine staining and in vitro cytokine production assays to compare the cytokine profile of CD4+ and CD8+ T cells in tumors harvested from WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- mice. IL-17 production in B16 tumors was markedly augmented in the absence of IFN-gamma, with an increase in the number of tumor-infiltrating Th17 cells (Fig. 2 A, top). IL-17 expression was also elevated in MB49 tumors grown in IFN-gamma-/- mice (Fig. 2 A, bottom). Further, ELISA analyses indicated a >10-fold increase in secreted IL-17 by B16 tumor-infiltrating CD4+ T cells in IFN-gamma-/- mice, which was again abrogated in IFN-gamma-/-IL-17-/- double KO mice (Fig. 2 B). Notably, we observed only minimal levels of IL-17 production by CD8+ T cells in both B16 and MB49 tumors ().
###end p 14
###begin p 15
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 97 105 97 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 181 189 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 296 304 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 374 375 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 383 384 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 403 406 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 398 406 390 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 436 444 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 447 452 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 639 654 631 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Yi et al., 2008</xref>
###xml 734 735 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 778 783 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 788 797 780 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;</italic>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
We observed an increased infiltration of CD4+ and CD8+ T cells in tumors grown in IL-17-/- mice (Fig. 2 C, top two rows). Furthermore, tumor-infiltrating CD8+ and CD4+ T cells from IL-17-/- mice produced more IFN-gamma relative to WT control mice, as assessed by intracellular cytokine staining (Fig. 2 C). The increase in IFN-gamma production by both tumor-infiltrating CD4+ and CD8+ T cells from IL-17-/- mice was confirmed by ELISA (Fig. 2 D). IL-17 ablation only modestly increased the percentage of tumor-infiltrating regulatory T cells (). It has been reported that IL-17 ablation does not affect the function of regulatory T cells (Yi et al., 2008). No correlation was observed with Th2-type immune responses as measured by CD4+ T cell-mediated IL-4 production caused by IL-17 and IFN-gamma ablation (Fig. S2 B).
###end p 15
###begin title 16
IL-17 activates Stat3 in both tumor and stromal cells in the tumor microenvironment
###end title 16
###begin p 17
###xml 293 308 293 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Yu et al., 2007</xref>
###xml 440 443 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 435 443 435 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 454 457 450 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 445 457 445 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 472 475 464 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 480 483 472 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 463 483 459 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 651 654 643 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 769 772 757 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 760 772 752 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 812 821 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;</italic>
###xml 920 923 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 928 931 908 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 911 931 895 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 955 958 931 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 946 958 926 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 965 973 941 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 1084 1092 1060 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 959 963 <span type="species:ncbi:10090">mice</span>
The underlying mechanisms by which Th17 promoted tumor growth was still unknown. Because Stat3 activation in tumor cells and tumor-associated inflammatory cells plays a critical role in tumor progression by augmenting tumor survival and tumor angiogenesis, and suppressing antitumor immunity (Yu et al., 2007), we explored the possibility that IL-17 mediates tumor growth via activation of Stat3. Stat3 activity in B16 tumors from WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- mice was examined by immunofluorescence staining of phosphorylated Stat3 (phospho-Stat3) in situ. We observed reduced phospho-Stat3 levels in B16 tumors grown in IL-17-/- mice compared with WT controls. In addition, Stat3 activity was drastically increased in tumors grown in IFN-gamma-/- mice, suggesting an inhibitory role of IFN-gamma on tumor Stat3 activation. Stat3 phosphorylation was diminished in tumors harvested from IFN-gamma-/-IL-17-/- compared with IFN-gamma-/- mice (Fig. 3 A). Immunofluorescence staining results were confirmed by Western blotting using an antibody for phospho-Stat3 (Fig. 3 B). Collectively, these results indicated that the levels of IL-17 positively correlated with Stat3 activity in growing tumors.
###end p 17
###begin p 18
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumorigenic effects of IL-17 are associated with Stat3 activation and up-regulation of oncogenic genes.</bold>
###xml 144 147 144 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 158 161 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 149 161 149 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 176 179 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 184 187 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 167 187 163 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 295 300 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 671 676 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 806 807 791 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
Tumorigenic effects of IL-17 are associated with Stat3 activation and up-regulation of oncogenic genes. B16 tumors were harvested from WT, IL-17-/-, IFN-gamma-/-, and IFN-gamma-/-IL-17-/- mice 20 d after tumor challenge. (A and B) Stat3 activation in B16 tumors in vivo is notably diminished by IL-17 ablation. (A) Frozen tumor sections were stained with antibodies specific to phospho-Stat3 (pStat3; green). Results are representative of three independent experiments. Bar, 100 microm. (B) Western blot analysis of phospho-Stat3, total Stat3, and beta-actin in protein extracts prepared from freshly harvested B16 tumors (representative of three experiments). (C and D) IL-17 deletion inhibits expression of Stat3-downstream oncogenic genes. Western blot analysis of tumor protein extracts to detect Bcl-xL, Bcl-2, vascular endothelial growth factor, MMP9, and beta-actin protein levels (representative of two independent experiments).
###end p 18
###begin p 19
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 194 197 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 197 185 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 204 212 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 314 317 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 305 317 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 381 384 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 389 392 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 372 392 364 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 399 407 387 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
We next tested whether increased IL-17 expression affected downstream Stat3 target genes. We found that Bcl family members, including Bcl-2 and Bcl-xL, were up-regulated in tumors from IFN-gamma-/- mice (Fig. 3 C). In addition, vascular endothelial growth factor and MMP9 were up-regulated in tumors from IFN-gamma-/- mice, and their expression was reduced in tumors from IFN-gamma-/-IL-17-/- mice (Fig. 3 D). These results suggested that IL-17 promoted Stat3 activity in tumors, leading to up-regulation of antiapoptotic and angiogenic genes.
###end p 19
###begin p 20
###xml 302 310 302 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 603 608 <span type="species:ncbi:9606">human</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
To investigate whether IL-17 signals directly through Stat3, we cultured B16 tumor cells, normal fibroblasts, endothelial cells, splenic DCs, and non-DC myeloid cells in the presence of recombinant mouse IL-17 or control. Results from these experiments showed that IL-17 indeed induced Stat3 activity (Fig. 4 A). Although IL-17 induced Stat3 activity in all tested target cells, it did so with significantly different kinetics (Fig. 4 A). Normal fibroblasts and endothelial cells were included to test IL-17 response, as they are major components of the tumor microenvironment. Similarly, we found that human recombinant IL-17 significantly stimulated Stat3 phosphorylation in several human cancer cell lines (). We further confirmed the expression of IL-17 receptor in tumor cells and fibroblasts (). These results suggested that induction of Stat3 activation in tumor cells and elements of the tumor microenvironment by IL-17 occurred through induction of an intermediary factor rather than directly.
###end p 20
###begin p 21
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17 activates Stat3 in tumor and tumor stromal cells through an IL-6&#8211;dependent mechanism.</bold>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 891 892 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1302 1303 1292 1293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
IL-17 activates Stat3 in tumor and tumor stromal cells through an IL-6-dependent mechanism. (A) The kinetics of Stat3 activation in B16 melanoma cells, MEFs, endothelial cells (ECP), splenic CD11c+ DCs, or splenic CD11b+ myeloid cells after stimulation with recombinant IL-17. Western blots of phospho-Stat3, total Stat3, and beta-actin are shown and are representative of two independent experiments. (B and C) IL-17 induces IL-6 expression in tumor and various tumor stromal cells. (B) IL-6 levels in B16 cells treated for 24 h with recombinant IL-17 were assessed by quantitative real-time PCR (left) and ELISA (second from left). IL-6 induction in MB49 tumor cells (middle), MEFs (second from right), and endothelial cells (ECP; right) by recombinant IL-17 treatment is shown (from three independent experiments; P < 0.0001). Data represent means +/- SEM. (C) Production of IL-6 by CD11c+ DCs upon IL-17 stimulation, as determined by ELISA (from three independent experiments; P = 0.0002). Data represent means +/- SEM. (D) IL-17-induced Stat3 activation is IL-6 dependent. (top) MB49 tumor cells were incubated with IL-17 with or without anti-IL-6 or -IL-10 antibodies, and Western blots were performed for phospho-Stat3, total Stat3, and beta-actin protein levels. (bottom) MEFs and splenic CD11c+ DCs were stimulated with IL-17 in the presence of IL-6-neutralizing antibodies or control IgG (representative of three independent experiments).
###end p 21
###begin title 22
IL-17 activates Stat3 via IL-6 induction
###end title 22
###begin p 23
###xml 62 81 62 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Hirano et al., 2000</xref>
###xml 284 302 284 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Ogura et al., 2008</xref>
###xml 600 615 600 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, B and C</xref>
###xml 895 916 895 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Numasaki et al., 2005</xref>
###xml 1442 1450 1442 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 1356 1361 <span type="species:ncbi:10090">mouse</span>
###xml 1529 1534 <span type="species:ncbi:9606">human</span>
IL-6 is a Stat3 activator and is elevated in diverse cancers (Hirano et al., 2000). IL-17 has recently been reported to stimulate production of IL-6 and Stat3 activation through a positive feedback loop, in inflammatory cells as well as fibroblasts, in an autoimmune disease setting (Ogura et al., 2008). We therefore determined whether IL-6 mediated IL-17-driven Stat3 activation in a tumor setting. We found that IL-17 stimulated IL-6 production by B16 and MB49 tumor cells in vitro, in addition to other cell types that constitute the tumor stroma such as fibroblasts, endothelial cells, and DCs (Fig. 4, B and C). The levels of IL-6 per cell produced by the tested tumor cells were lower than those produced by fibroblasts and endothelial cells. Although treating the tumor cells with recombinant IL-17 only modestly increased their proliferation (), which is consistent with another study (Numasaki et al., 2005), similar treatment of endothelial cells led to increased expression of several Stat3 downstream genes that are involved in cell migration (Fig. S5 B). In addition, IL-17-mediated increased secretion of angiogenic factors by endothelial cells induced endothelial cell migration in a Stat3-dependent manner (Fig. S5 C). Importantly, neutralizing IL-6 but not IL-10 (another Stat3 activator) with a blocking mAb reduced Stat3 activation in (mouse embryonic fibroblasts) MEFs, DCs, and MB49 tumor cells after IL-17 stimulation (Fig. 4 D). Similarly, anti-IL-6 antibodies abrogated IL-17-induced Stat3 activation in human cancer cells (Fig. S3 B). These results indicated that IL-17 activated Stat3 through IL-6 in diverse types of cancer and nontransformed cells constituting the tumor stroma.
###end p 23
###begin title 24
In vivo IL-6 blockade partially reverses tumor progression in the setting of high intratumoral IL-17
###end title 24
###begin p 25
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 205 213 205 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 254 257 250 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 245 257 245 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 339 342 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 347 350 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 330 350 326 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 357 365 349 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 459 460 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 527 535 519 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 645 648 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 636 648 628 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 771 774 755 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 779 782 763 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 762 782 750 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 1242 1245 1222 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1233 1245 1217 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 1252 1260 1232 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 1556 1557 1536 1537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1570 1578 1550 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 753 756 <span type="species:ncbi:10116">rat</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 1174 1177 <span type="species:ncbi:10116">rat</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
We first assessed whether IL-17 affected IL-6 production by tumors in vivo. Freshly harvested B16 tumor cells from WT mice produced relatively high levels of IL-6, which were reduced after IL-17 ablation (Fig. 5 A). In addition, tumors grown in IFN-gamma-/- mice produced a markedly increased level of IL-6 when compared with the IFN-gamma-/-IL-17-/- mice (Fig. 5 A). More detailed analysis of growing tumors indicated that tumor-associated immune cells (CD45+) were the main source of IL-6 when compared with the tumor cells (Fig. 5 B). To directly test whether IL-17 could promote tumor growth through IL-6-mediated Stat3 activation, IFN-gamma-/- mice were challenged with B16 melanoma, followed by administration of IL-6-neutralizing mAbs or control rat IgG. IFN-gamma-/-IL-17-/- mice challenged with B16 melanoma but without anti-IL-6 antibody treatment were included as an additional control. Because IL-6 was shown to promote Th17 cell differentiation, we did not start anti-IL-6 treatment until 6 d after tumor inoculation, a time at which tumor-infiltrating Th17 cells were detectable (unpublished data). We found that administration of monoclonal anti-IL-6 but not rat IgG antibodies significantly inhibited tumor growth in IFN-gamma-/- mice (Fig. 5 C), suggesting that IL-17-induced tumor progression is at least in part mediated by IL-6. Consistent with a role for IL-6 in mediating tumor Stat3 activation and tumor growth promotion, neutralizing IL-6 in vivo reduced Stat3 activity and the expression of its downstream antiapoptotic gene, Bcl-xL, in tumors (Fig. 5 D).
###end p 25
###begin p 26
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumor-derived IL-6 mediates tumorigenic effects of IL-17.</bold>
###xml 392 395 392 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 387 395 387 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 418 421 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 409 421 409 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 435 438 427 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 443 446 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 426 446 422 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 571 572 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 596 597 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 682 683 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 746 749 732 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 737 749 727 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 763 766 745 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 771 774 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 754 774 740 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 817 818 797 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 878 881 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 895 898 867 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 903 906 875 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 869 906 849 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup> and IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 966 969 934 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 957 969 929 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 1082 1083 1048 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1190 1191 1156 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 907 911 <span type="species:ncbi:10090">mice</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
###xml 1033 1036 <span type="species:ncbi:10116">rat</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
###xml 1291 1295 <span type="species:ncbi:10090">mice</span>
Tumor-derived IL-6 mediates tumorigenic effects of IL-17. (A and B) IL-6 secretion in the tumor microenvironment correlates with IL-17 levels. (A) Single-cell suspensions prepared from B16 tumors harvested from the indicated mice were cultured in vitro overnight; supernatants were then collected and assayed for IL-6 levels, combining four mice from two independent experiments (WT vs. IL-17-/-, P = 0.0026; IFN-gamma-/- vs. IFN-gamma-/-IL-17-/-, P = 0.005). Data are means +/- SEM. (B) Single-cell suspensions prepared from MB49 tumors were enriched for CD45. Both CD45+ (immune cells) and CD45- (tumor cells) were cultured overnight before supernatants were collected for ELISA (n = 4 mice representing three independent experiments; IFN-gamma-/- vs. IFN-gamma-/-IL-17-/-, P = 0.03). Data are means +/- SEM. (C) 105 B16 tumor cells were injected subcutaneously into IFN-gamma-/- and IFN-gamma-/-IL-17-/- mice. 6 d after tumor implantation, tumor-bearing IFN-gamma-/- mice were treated with IL-6-neutralizing antibodies or control rat IgG every other day. Data are means +/- SEM (n = 7 mice from two independent experiments). (D) Western blot analyses of phospho-Stat3, total Stat3, Bcl-xL, and beta-actin levels from protein extracts prepared from B16 tumors harvested from the indicated mice (representative of two independent experiments).
###end p 26
###begin p 27
###xml 484 499 484 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Yu et al., 2007</xref>
###xml 614 631 614 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Chen et al., 2006</xref>
###xml 633 652 633 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Harris et al., 2007</xref>
###xml 997 1018 994 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Numasaki et al., 2003</xref>
###xml 1020 1041 1017 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Numasaki et al., 2005</xref>
###xml 1043 1059 1040 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Nam et al., 2008</xref>
###xml 1061 1078 1058 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Xiao et al., 2009</xref>
###xml 1262 1265 1259 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1257 1265 1254 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 1272 1292 1269 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kryczek et al., 2009</xref>
###xml 1266 1270 <span type="species:ncbi:10090">mice</span>
In summary, we have shown that IL-17 can promote tumor growth. Our results suggested that the IL-17-mediated tumor-promoting role involves a direct effect on tumor through IL-6 induction, which in turn activates Stat3 in both tumor as well as nontransformed cells constituting the tumor microenvironment. IL-6 activation of Stat3 in tumor cells results in increases in antiapoptotic, proproliferation, and proangiogenic genes, as well as suppression of certain proinflammatory genes (Yu et al., 2007). IL-6-induced Stat3 signaling in T cells is also critical in promoting Th17 cell differentiation and expression (Chen et al., 2006; Harris et al., 2007). Given that TGF-beta, the other cytokine involved in Th17 cell differentiation, is also expressed at high levels in tumors, IL-17-induced IL-6 production can generate an autoamplification loop for Th17 cells in the tumor microenvironment. Consistent with our findings, several publications suggested a role of IL-17 in promoting tumor growth (Numasaki et al., 2003; Numasaki et al., 2005; Nam et al., 2008; Xiao et al., 2009), although the mechanism was not well addressed in these studies. However, a recent paper showed that, in a different tumor system (MC38 sarcoma), tumors growth was increased in IL-17-/- mice (Kryczek et al., 2009). These findings suggest that the role of IL-17 in cancer is context and system dependent, like many other cytokines such as TNF-alpha. Additional studies are required to reveal why IL-17 can have opposite roles in modulating growth in different tumor systems.
###end p 27
###begin p 28
###xml 459 467 455 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-12p35</italic>
###xml 513 521 509 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-23p19</italic>
###xml 531 553 527 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Langowski et al., 2006</xref>
###xml 752 776 748 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kortylewski et al., 2009</xref>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
The opposing functions of IFN-gamma and IL-17 as anticarcinogenic and protumor growth effector cytokines extend an emerging concept that the qualitative nature of the immune response determines whether it will predominantly inhibit tumor growth or promote cancer development. Recently, analogous opposing effects of the two IL-12 family members, IL-12 and IL-23, in tumor inhibition versus promotion have been ascertained based on enhanced tumor formation in IL-12p35 KO mice versus diminished tumor formation in IL-23p19 KO mice (Langowski et al., 2006). We subsequently reported that Stat3 signaling in tumors and their microenvironment determined the balance between these cytokines by transcriptionally activating IL-23p19 and inhibiting IL-12p35 (Kortylewski et al., 2009). The current work is among the first examples by which a qualitatively distinct (Th17) endogenous T cell immune response can be cancer promoting. Further, it adds a new element to the link between immune responses that either depend on or induce Stat3 signaling and Stat3-mediated protumor growth.
###end p 28
###begin title 29
MATERIALS AND METHODS
###end title 29
###begin title 30

###end title 30
###begin title 31
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 31
###begin p 32
###xml 16 19 12 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 7 19 7 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 156 159 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 151 159 147 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 195 213 191 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Nakae et al., 2002</xref>
###xml 555 556 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 294 299 <span type="species:ncbi:10090">Mouse</span>
###xml 625 640 <span type="species:ncbi:10090">transgenic mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 815 818 <span type="species:ncbi:10116">rat</span>
###xml 929 933 <span type="species:ncbi:10090">Mice</span>
WT and IFN-gamma-/- C57BL/6 mice were purchased from the National Cancer Institute and the Jackson Laboratory, respectively. The generation of C57BL/6 IL-17-/- mice has been previously reported (Nakae et al., 2002), and the mice were provided by Y. Iwakura (University of Tokyo, Tokyo, Japan). Mouse care and experimental procedures were performed under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Research Animal Care Committee of the City of Hope Medical Center. For tumor challenge, 105 B16 tumor cells were injected subcutaneously into 8-12-wk-old WT or transgenic mice, and tumor growth was monitored every other day. For IL-6 neutralization experiments in vivo, mice were treated with 125 microg anti-IL-6 antibodies (eBioscience) or control rat IgG (Jackson ImmunoResearch Laboratories) injected i.v. on days 6, 8, 10, 12, and 14 after tumor inoculation. Mice were sacrificed after 2-3 wk from tumor inoculation or when tumor volume exceeded 1.5 cm in diameter.
###end p 32
###begin title 33
Cell lines.
###end title 33
###begin p 34
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
B16 and MB49 cell lines were originally obtained from American Type Culture Collection and were maintained in our laboratory. Endothelial cell lines derived from mouse prostate were provided by J. Fidler (M.D. Anderson Cancer Center, Houston, TX).
###end p 34
###begin title 35
T cell adoptive transfer.
###end title 35
###begin p 36
###xml 36 39 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 27 39 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup></italic>
###xml 52 55 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 60 63 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 43 63 39 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;<sup>&#8722;/&#8722;</sup>IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 260 261 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
T cells were enriched from IFN-gamma-/- or IFN-gamma-/-IL-17-/- mice. Specifically, non-T cells were depleted with biotin-labeled mAbs, including anti-B220, Gr-1, Mac-1, CD11c, DX5, and Ter119, using a magnetic purification system from Miltenyi Biotec. TCRbeta+ T cell purity was >90%, as determined by flow cytometry.
###end p 36
###begin title 37
Preparation of tumor-infiltrating immune cells.
###end title 37
###begin p 38
###xml 84 108 84 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Kortylewski et al., 2005</xref>
###xml 361 362 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
The procedure for isolating immune cells from tumors has been described previously (Kortylewski et al., 2005). In brief, freshly excised tumor tissues were gently minced and digested for 30 min at 37degreesC by collagenase D/DNase I (Roche). Cell suspensions were filtered through a 70-microm cell strainer, and dead cells were removed by centrifugation at 600 g over a Histopaque gradient (Sigma-Aldrich).
###end p 38
###begin title 39
Flow cytometry.
###end title 39
###begin p 40
###xml 390 405 382 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Yi et al., 2008</xref>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
The FITC-, PE-, allophycocyanin (APC)-, or Cy7-APC-conjugated antibodies specific to CD4, CD8, IL-17, and IFN-gamma were purchased from BD; PE-labeled antibody against mouse Foxp3 was purchased from eBioscience, and PE-labeled antibody for IL-17R was purchased from R&D Systems. Intracellular staining for IL-17 and IFN-gamma was performed according to the manufacturer's instructions (BD; Yi et al., 2008). In brief, cells were stimulated for 5 h with PMA and ionomycin (Sigma-Aldrich) in the presence of Golgi-Stop reagent (BD). Cells were harvested, washed, and stained with anti-CD4 or -CD8 in the presence of FcR-Block (BD). After the wash, cells were fixed, permeabilized, and stained with cytokine-specific or control isotype antibodies for 30 min on ice. Multiple-color FACS analysis was performed using a three-laser CyAn Immunocytometry System (Dako). Dead cells were excluded by the Fixable Aqua Dead Cell Stain Kit (Invitrogen).
###end p 40
###begin title 41
ELISA assays.
###end title 41
###begin p 42
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 156 157 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 180 181 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
105 sorted tumor-infiltrating CD4+, CD8+ T cells were cultured for 24 h in a U-bottom 96-well plate with plate-bound CD3 and 2 microg/ml of soluble CD28. 106 enriched splenic CD11c+ or cultured cells/ml were stimulated for 24 h with 10 ng/ml of recombinant IL-17. IFN-gamma, IL-17, IL-6, and IL-4 concentrations in culture supernatants were measured using ELISA kits from R&D Systems.
###end p 42
###begin title 43
Immunofluorescence staining.
###end title 43
###begin p 44
###xml 299 323 295 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Kortylewski et al., 2005</xref>
5-microm sections of flash-frozen tumor specimens were fixed in acetone, permeabilized with methanol, stained with antibodies specific to tyrosine-phospho-Stat3 (Santa Cruz Biotechnology, Inc.) and detected with secondary antibodies conjugated Alexa Fluor 488 (Invitrogen), as previously described (Kortylewski et al., 2005). After staining with Hoechst 33342 (Invitrogen) to visualize cell nuclei, slides were mounted and analyzed by fluorescence microscopy.
###end p 44
###begin title 45
Statistical analysis.
###end title 45
###begin p 46
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The unpaired t test was used to calculate the two-tailed p-value. The two-way analysis of variance test was used to calculate the p-value for tumor growth. Data were analyzed using Prism software (GraphPad Software, Inc.).
###end p 46
###begin title 47
Online supplemental material.
###end title 47
###begin p 48
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 298 <span type="species:ncbi:9606">human</span>
Fig. S1 shows the production of IL-17 in tumor-infiltrating CD8+ T cells, determined by intracellular staining and ELISA. Fig. S2 indicates that ablating IFN-gamma or IL-17 did not significantly affect the T reg cell percentage and IL-4 production. Fig. S3 shows that IL-17 activates Stat3 in human tumor cell lines in an IL-6-dependent manner. Fig. S4 confirms IL-17 receptor expression on B16 tumor cells and MEFs. Fig. S5 depicts the effect of IL-17 on tumor cell proliferation and endothelial cell migration. Online supplemental material is available at .
###end p 48
###begin title 49
Supplementary Material
###end title 49
###begin title 50
[Supplemental Material]
###end title 50
###begin p 51
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 57 65 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17<sup>&#8722;/&#8722;</sup></italic>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
We thank Dr. Y. Iwakura for generously providing us with IL-17-/- mice; Dr. Y. Liu for superb assistance; the members of the Flow Cytometry Core, the Pathology Core, and the Animal Facility at the City of Hope Medical Center for their contributions; and Dr. S. da Costa for editing the manuscript.
###end p 51
###begin p 52
This study was supported by the National Institutes of Health (grants R01CA122976, R01CA115815, and R01 AI066008).
###end p 52
###begin p 53
The authors have no conflicting financial interests.
###end p 53
###begin article-title 54
T(H)-17 cells in the circle of immunity and autoimmunity.
###end article-title 54
###begin article-title 55
Stat3 as an oncogene.
###end article-title 55
###begin article-title 56
Th17 cells: a new fate for differentiating helper T cells.
###end article-title 56
###begin article-title 57
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells.
###end article-title 57
###begin article-title 58
Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion.
###end article-title 58
###begin article-title 59
Interferons, immunity and cancer immunoediting.
###end article-title 59
###begin article-title 60
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
###end article-title 60
###begin article-title 61
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.
###end article-title 61
###begin article-title 62
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.
###end article-title 62
###begin article-title 63
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
###end article-title 63
###begin article-title 64
###xml 112 138 112 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 112 138 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge.
###end article-title 64
###begin article-title 65
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.
###end article-title 65
###begin article-title 66
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.
###end article-title 66
###begin article-title 67
Endogenous IL-17 contributes to reduced tumor growth and metastasis.
###end article-title 67
###begin article-title 68
IL-23 promotes tumour incidence and growth.
###end article-title 68
###begin article-title 69
###xml 29 34 <span type="species:ncbi:9606">human</span>
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
###end article-title 69
###begin article-title 70
Tumor-specific Th17-polarized cells eradicate large established melanoma.
###end article-title 70
###begin article-title 71
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses.
###end article-title 71
###begin article-title 72
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.
###end article-title 72
###begin article-title 73
Interleukin-17 promotes angiogenesis and tumor growth.
###end article-title 73
###begin article-title 74
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
###end article-title 74
###begin article-title 75
Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction.
###end article-title 75
###begin article-title 76
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.
###end article-title 76
###begin article-title 77
Th17: an effector CD4 T cell lineage with regulatory T cell ties.
###end article-title 77
###begin article-title 78
IL-17 family cytokines and the expanding diversity of effector T cell lineages.
###end article-title 78
###begin article-title 79
IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation.
###end article-title 79
###begin article-title 80
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.
###end article-title 80
###begin article-title 81
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
###end article-title 81
###begin article-title 82
###xml 32 40 <span type="species:ncbi:9606">patients</span>
The prevalence of Th17 cells in patients with gastric cancer.
###end article-title 82
###begin article-title 83
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients.
###end article-title 83
###begin p 84
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Abbreviations used: MEF, mouse embryonic fibroblast; phospho-Stat3, phosphorylated Stat3.
###end p 84

